Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance

Sponsor
Assistance Publique Hopitaux De Marseille
Study ID
NCT03833440
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Durvalumab (MEDI4736) — DRUG
    1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days c=cycle D= day
  • Monalizumab (IPH2201) — DRUG
    1500 mg, every 4 weeks. CXD1 for each cycle, 1 cycle = 28 days c=cycle D= day
  • Oleclumab (MEDI9447) — DRUG
    3000 mg every 2 week x 4 doses, followed by 3000 mg every 4 weeks. C1D1, C1D15, C2D1, C2D15 and CXD1 for the orther cycles, 1 cycle = 28 days. c=cycle D= day
  • Ceralasertib (AZD6738) — DRUG
    240 mg bid in Cycle 1, Days 1-7, followed by 7 days on treatment in each cycle between Days 22 and 28. CxD22-D28 for each cycle, 1 cycle = 28 days EXCEPT FOR CYCLE 1 : at C1D1,C1D29 and cycle 1 = 35 days c=cycle D= day
  • DOCETAXEL — DRUG
    75 mg/m2, every 3 weeks. CxD1 for each cycle, 1 cycle = 21 days c=cycle D= day
  • Savolitinib — DRUG
    600 mg QD 1 cycle = 28 days

Study Details

Research Hypothesis Lung cancer is the leading cause of cancer-related mortality in France and in western countries, accounting for more than 1.8 million new cases and 1.5 million deaths worldwide in 2012. Recent advances in the management of patients with Non-small Cell Lung Cancer Patients (NSCLC) include the use of therapies targeting oncogenes but a molecular alteration is currently found in only the half of the non-squamous NSCLC . More recently, immune check point inhibitors (ICI), firstly targeting PD-(L)1, became available and demonstrate an overall survival advantage over standard second-line chemotherapy both in squamous and non-squamous NSCLC. Unfortunately, this global overall survival benefit is driven by approximately 20% of the patient's population while a large majority of patients is in fact progressing in the first weeks of treatment. In the context of personalized medicine, innovative immunotherapy strategies in oncology are based on the principle of immune-contexture and require: * The identification of biomarkers for assessing the specific immune-contexture of each patient (microenvironment, tumors and effector cells) * The development of new treatments targeting their appropriate effector cells in monotherapy or combination treatments. The current PIONEER-Clinical study is aimed at assessing how to overcome resistance to ICIs monotherapies or ICI in combination with platinum-based chemotherapies, with experimental precision immunotherapies combined to Durvalumab in 2nd, 3rd or 4th line, in advanced NSCLC progressors patients after up to 18more than 6 w. of anti PD (L) 1. for ICIs monotherapies and after more than 12w. of anti PD(L)1 in combination with chemotherapies. Some supplementary blood and tissue samples are aimed at identification of personalized patients' biomarkers, correlation of them with the efficacy endpoints, in order to better understand mechanisms of resistance and improve their future treatment.

Key Dates

Start date
Oct 8, 2019
Status verified
May 2024
Primary completion
Oct 31, 2024
Completion
Feb 28, 2025

Study Design

Enrollment
114 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Durvalumab + Monalizumab
  • Experimental: Durvalumab + MEDI9447
  • Experimental: Durvalumab + AZD6738
  • Active Comparator: Docetaxel
  • Experimental: durvalumab+savolitinib

Primary Outcome Measure

the 12-week Disease Control Rate [ Time Frame: 12 weeks ]

Related Studies